Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26724224,total clearance,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],16.00,1309,DB01016,Glyburide
,26724224,total clearance,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],6.72,1310,DB01016,Glyburide
,26724224,half-life,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),h,1.64,1311,DB01016,Glyburide
,26724224,half-life,"Compared with normothermia, mild hypothermia significantly decreased the total clearance of glibenclamide (16.00±4.1-6.72±2.1mL/min/kg; p<0.01), and there was a non-significant trend in a slightly higher half-life, (1.64±0.34-2.71±1.7h, p=0.157).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),h,2.71,1312,DB01016,Glyburide
,26724224,Area under the plasma concentration versus time curve (AUClast),"Area under the plasma concentration versus time curve (AUClast) in the hypothermic group was increased (33.2±11-77.8±18hng/mL, p<0.01).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[hng] / [ml],33.2,1313,DB01016,Glyburide
,26724224,Area under the plasma concentration versus time curve (AUClast),"Area under the plasma concentration versus time curve (AUClast) in the hypothermic group was increased (33.2±11-77.8±18hng/mL, p<0.01).",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[hng] / [ml],77.8,1314,DB01016,Glyburide
,26724224,total clearance,"Moreover, mild hypothermia reduced the total clearance of diclofenac (10.33±1.53-7.20±1.66mL/min/kg, p<0.01), indicating that the CYP2C9 activity was compromised in reduced temperature.",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],10.33,1315,DB01016,Glyburide
,26724224,total clearance,"Moreover, mild hypothermia reduced the total clearance of diclofenac (10.33±1.53-7.20±1.66mL/min/kg, p<0.01), indicating that the CYP2C9 activity was compromised in reduced temperature.",Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26724224/),[ml] / [kg·min],7.20,1316,DB01016,Glyburide
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB01016,Glyburide
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB01016,Glyburide
,2493353,elimination half-life,Estimated mean elimination half-life of glyburide was 3.3 +/- 1.1 hours for EM and 2.5 +/- 0.4 hours for PM.,The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,3.3,2489,DB01016,Glyburide
,2493353,elimination half-life,Estimated mean elimination half-life of glyburide was 3.3 +/- 1.1 hours for EM and 2.5 +/- 0.4 hours for PM.,The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,2.5,2490,DB01016,Glyburide
,2493353,apparent elimination half-life,"In one subject (EM), with reduced excretion of 30H, glyburide was detected in plasma at 24 and 30 hours and the apparent elimination half-life was 9.3 hours.",The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,9.3,2491,DB01016,Glyburide
,30245720,flow rate,Mobile phase consisting of acetonitrile (0.1% formic acid) and water (0.1% formic acid) was pumped in binary gradient mode at flow rate of 150 μL/min.,"Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),[μl] / [min],150,8842,DB01016,Glyburide
,30245720,elution time,"Glibenclamide and IS elution time was about 1.0 min, and total run time was 2.0 min.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),min,1.0,8843,DB01016,Glyburide
,30245720,total run time,"Glibenclamide and IS elution time was about 1.0 min, and total run time was 2.0 min.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),min,2.0,8844,DB01016,Glyburide
,30245720,Accuracy,"Accuracy of the method at LQC, MQC, and HQC was 109.7% (± 6.7), 93.6% (± 0.4), and 99.3% (± 1.9), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,109.7,8845,DB01016,Glyburide
,30245720,Accuracy,"Accuracy of the method at LQC, MQC, and HQC was 109.7% (± 6.7), 93.6% (± 0.4), and 99.3% (± 1.9), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,93.6,8846,DB01016,Glyburide
,30245720,Accuracy,"Accuracy of the method at LQC, MQC, and HQC was 109.7% (± 6.7), 93.6% (± 0.4), and 99.3% (± 1.9), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,99.3,8847,DB01016,Glyburide
,30245720,Recovery,"Recovery at LLQC, MQC, and HQC was 104.2% (± 4.9), 100.6% (± 0.9), and 102.9% (± 5.8), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,104.2,8848,DB01016,Glyburide
,30245720,Recovery,"Recovery at LLQC, MQC, and HQC was 104.2% (± 4.9), 100.6% (± 0.9), and 102.9% (± 5.8), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,100.6,8849,DB01016,Glyburide
,30245720,Recovery,"Recovery at LLQC, MQC, and HQC was 104.2% (± 4.9), 100.6% (± 0.9), and 102.9% (± 5.8), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,102.9,8850,DB01016,Glyburide
,14600799,m,Quantitation was preformed by using multiple reaction monitoring (MRM) of the precursor ion (m/z 494.2-->368.8) and the related product ion (m/z 446.0-->347.3) using the internal standard method.,LC-APCI-MS-MS methodology for determination of glybenclamide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14600799/),,494.2,10629,DB01016,Glyburide
,14600799,m,Quantitation was preformed by using multiple reaction monitoring (MRM) of the precursor ion (m/z 494.2-->368.8) and the related product ion (m/z 446.0-->347.3) using the internal standard method.,LC-APCI-MS-MS methodology for determination of glybenclamide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14600799/),,446.0,10630,DB01016,Glyburide
,8137685,half-life,"Serum glyburide levels declined in three different phases, with a terminal gamma-phase between 18 and 48 h having a mean +/- SD half-life of 15.0 +/- 6.7 h.",Slow elimination of glyburide in NIDDM subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137685/),h,15.0,15127,DB01016,Glyburide
over,8137685,half-lives,Two patients had half-lives over 20 h.,Slow elimination of glyburide in NIDDM subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137685/),h,20,15128,DB01016,Glyburide
,3100314,bioavailabilities,"Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24.","Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100314/),,0.69,15864,DB01016,Glyburide
,3100314,bioavailabilities,"Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24.","Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100314/),,0.49,15865,DB01016,Glyburide
,3100314,bioavailabilities,"Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24.","Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100314/),,0.24,15866,DB01016,Glyburide
,3100314,elimination half-life,"The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1.","Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100314/),h,1.5,15867,DB01016,Glyburide
,3100314,systemic clearance,"The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1.","Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100314/),[l] / [kg],0.095,15868,DB01016,Glyburide
,3100314,apparent volume of distribution,"The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1.","Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100314/),[l] / [kg],0.20,15869,DB01016,Glyburide
,9812177,peak concentrations (Cmax),Mean peak concentrations (Cmax) of 2.86 to 6.50 mg/L were achieved within 1.22 to 2.75 hours of administration.,Clinical pharmacokinetics of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[mg] / [l],2.86 to 6.50,18714,DB01016,Glyburide
,9812177,bioavailability,"When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations.",Clinical pharmacokinetics of nimesulide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,54 to 64,18715,DB01016,Glyburide
,9812177,apparent volume of distribution,Nimesulide is rapidly distributed and has an apparent volume of distribution ranging between 0.18 and 0.39 L/kg.,Clinical pharmacokinetics of nimesulide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[l] / [kg],0.18 and 0.39,18716,DB01016,Glyburide
,9812177,unbound fraction,It is extensively bound to albumin; the unbound fraction in plasma was 1%.,Clinical pharmacokinetics of nimesulide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,1,18717,DB01016,Glyburide
,9812177,terminal elimination half-life,The estimated mean terminal elimination half-life varied from 1.80 to 4.73 hours.,Clinical pharmacokinetics of nimesulide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),h,1.80 to 4.73,18718,DB01016,Glyburide
,9812177,total plasma clearance,"The total plasma clearance of nimesulide, was 31.02 to 106.16 ml/h/kg, reflecting almost exclusive metabolic clearance.",Clinical pharmacokinetics of nimesulide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[ml] / [h·kg],31.02 to 106.16,18719,DB01016,Glyburide
,9812177,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",Clinical pharmacokinetics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),,0.1,18720,DB01016,Glyburide
,115986,lower detection limit,"The response was linear, and the lower detection limit was approximately 20 ng/ml.",Specific and sensitive high-performance liquid chromatographic determination of glyburide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/115986/),[ng] / [ml],20,22499,DB01016,Glyburide
,34242946,flow rate,"Chromatographic separation was carried out on ACQUITY UPLC BEH - C18 column (2.1 mm × 50 mm, 1.7 μm) with a mobile phase composed of acetonitrile - water (containing 1.0 mmol/L ammonium acetate) using gradient elution at a flow rate of 0.2 mL/min.",An UPLC - Q - Orbitrap method for pharmacokinetics and tissue distribution of four triterpenoids in rats after oral administration of Poria cocos ethanol extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34242946/),[ml] / [min],0.2,22716,DB01016,Glyburide
,7757317,"normalized AUCss,norm","The normalized AUCss,norm were 11.6 (5.0) kg x h x 1(-1) at glibenclamide monotherapy and 12.3 (5.1) kg x h x 1(-1) after combined medication, resulting in an AUC-ratio for glibenclamide of 109 (23%).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h·kg,11.6,22863,DB01016,Glyburide
,7757317,"normalized AUCss,norm","The normalized AUCss,norm were 11.6 (5.0) kg x h x 1(-1) at glibenclamide monotherapy and 12.3 (5.1) kg x h x 1(-1) after combined medication, resulting in an AUC-ratio for glibenclamide of 109 (23%).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h·kg,12.3,22864,DB01016,Glyburide
,7757317,AUC-ratio,"The normalized AUCss,norm were 11.6 (5.0) kg x h x 1(-1) at glibenclamide monotherapy and 12.3 (5.1) kg x h x 1(-1) after combined medication, resulting in an AUC-ratio for glibenclamide of 109 (23%).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),,109,22865,DB01016,Glyburide
,7757317,elimination half-lives,Mean elimination half-lives were determined as 2.7 (0.9) h after glibenclamide alone and 3.6 (1.9) h after nimodipine comedication.,The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h,2.7,22866,DB01016,Glyburide
,7757317,elimination half-lives,Mean elimination half-lives were determined as 2.7 (0.9) h after glibenclamide alone and 3.6 (1.9) h after nimodipine comedication.,The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h,3.6,22867,DB01016,Glyburide
,7757317,Cmax,"There was no evidence of significant alterations in glibenclamide efficiency as seen from glucose and insulin kinetics after the simultaneous administration of glibenclamide and nimodipine (insulin Cmax, 57.0 (30.8) mU/l after glibenclamide and 64.4 (32.1) mU/l after combined treatment).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),[mu] / [l],57.0,22868,DB01016,Glyburide
,7757317,Cmax,"There was no evidence of significant alterations in glibenclamide efficiency as seen from glucose and insulin kinetics after the simultaneous administration of glibenclamide and nimodipine (insulin Cmax, 57.0 (30.8) mU/l after glibenclamide and 64.4 (32.1) mU/l after combined treatment).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),[mu] / [l],64.4,22869,DB01016,Glyburide
,7757317,AUCss,"Nimodipine pharmacokinetics under nimodipine and glibenclamide steady-state conditions were similar to findings in literature: AUCss,norm 0.10 (0.04) microgram x h x 1(-1), Css,max 20.7 (8.3) microgram x 1(-1).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h·μg,0.10,22870,DB01016,Glyburide
,7757317,"Css,max","Nimodipine pharmacokinetics under nimodipine and glibenclamide steady-state conditions were similar to findings in literature: AUCss,norm 0.10 (0.04) microgram x h x 1(-1), Css,max 20.7 (8.3) microgram x 1(-1).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),μg,20.7,22871,DB01016,Glyburide
,7612921,limit of detection,The four sulfonylureas could be identified and measured with a precision of 5%-7% and a limit of detection close to 1-2 ng in injected external standards and 10-40 ng/ml in plasma samples.,Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612921/),ng,1-2,23927,DB01016,Glyburide
,7612921,limit of detection,The four sulfonylureas could be identified and measured with a precision of 5%-7% and a limit of detection close to 1-2 ng in injected external standards and 10-40 ng/ml in plasma samples.,Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612921/),[ng] / [ml],10-40,23928,DB01016,Glyburide
,24374443,flow rate,Potassium dihydrogen phosphate containing 0.25mL/L triethylamine at pH 3.5 (adjusted with 1:1 phosphoric acid) and acetonitrile (465: 535v/v) was delivered with injection volume of 100μL at flow rate of 1 mL/min at 25°C temperature.,Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374443/),[ml] / [min],1,26334,DB01016,Glyburide
,24374443,Maximum plasma concentrations Cmax,Maximum plasma concentrations Cmax was 131.856±8.050ng/ml for Glibenclamide (Mean ± SEM) and 511.106±12.675 ng/ml for Metformin HCl (Mean ±SEM).,Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374443/),[ng] / [ml],131.856,26335,DB01016,Glyburide
,24374443,Maximum plasma concentrations Cmax,Maximum plasma concentrations Cmax was 131.856±8.050ng/ml for Glibenclamide (Mean ± SEM) and 511.106±12.675 ng/ml for Metformin HCl (Mean ±SEM).,Pharmacokinetic studies of metformin and glibenclamide in normal human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374443/),[ng] / [ml],511.106,26336,DB01016,Glyburide
,12237477,metabolic debt repayment,Three episodes of 1 min ischemia in the lower limbs in humans reduced the metabolic debt repayment (expressed as AUC of reactive hyperaemia) following more prolonged ischemia (666.6+/-86.6 vs 500.0+/-33.5 ml/100 ml).,Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),ml,666.6,26737,DB01016,Glyburide
,12237477,metabolic debt repayment,Three episodes of 1 min ischemia in the lower limbs in humans reduced the metabolic debt repayment (expressed as AUC of reactive hyperaemia) following more prolonged ischemia (666.6+/-86.6 vs 500.0+/-33.5 ml/100 ml).,Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),ml,500.0,26738,DB01016,Glyburide
,12237477,AUC,Three episodes of 1 min ischemia in the lower limbs in humans reduced the metabolic debt repayment (expressed as AUC of reactive hyperaemia) following more prolonged ischemia (666.6+/-86.6 vs 500.0+/-33.5 ml/100 ml).,Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),ml,666.6,26739,DB01016,Glyburide
,12237477,AUC,Three episodes of 1 min ischemia in the lower limbs in humans reduced the metabolic debt repayment (expressed as AUC of reactive hyperaemia) following more prolonged ischemia (666.6+/-86.6 vs 500.0+/-33.5 ml/100 ml).,Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),ml,500.0,26740,DB01016,Glyburide
,12237477,AUC,"The administration of the ATP-dependent K(+) channel blocker glibenclamide was associated with a significant reduction in the AUC of reactive hyperaemia (666.6+/-86.6 vs 563.1+/-76.6 ml/100 ml), and with the removal of the protective effect produced by 3 episodes of 1 min ischemia (563.1+/-76.6 vs 551.8+/-71.3 ml/100 ml).",Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),[ml] / [100·ml],666.6,26741,DB01016,Glyburide
,12237477,AUC,"The administration of the ATP-dependent K(+) channel blocker glibenclamide was associated with a significant reduction in the AUC of reactive hyperaemia (666.6+/-86.6 vs 563.1+/-76.6 ml/100 ml), and with the removal of the protective effect produced by 3 episodes of 1 min ischemia (563.1+/-76.6 vs 551.8+/-71.3 ml/100 ml).",Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),[ml] / [100·ml],563.1,26742,DB01016,Glyburide
,12237477,AUC,"The administration of the ATP-dependent K(+) channel blocker glibenclamide was associated with a significant reduction in the AUC of reactive hyperaemia (666.6+/-86.6 vs 563.1+/-76.6 ml/100 ml), and with the removal of the protective effect produced by 3 episodes of 1 min ischemia (563.1+/-76.6 vs 551.8+/-71.3 ml/100 ml).",Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),[ml] / [100·ml],551.8,26743,DB01016,Glyburide
,12237477,peak,"Plasma level of glibenclamide reached the peak value of 1.295+/-0.15 micromol/l 2 h after drug administration, ranging around the 1 micromol/l concentration in the following 3 hours.",Acute effects of glibenclamide on reactive hyperaemia in the lower limbs in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12237477/),[μM] / [l],1.295,26744,DB01016,Glyburide
,2505996,areas under the blood concentration-time curves (AUC0-infinity),"The areas under the blood concentration-time curves (AUC0-infinity), with or without antacid, were 408.17 +/- 168.25 and 307.9 +/- 84.13 ng/ml (p less than 0.05), respectively.",Influence of antacids on the bioavailability of glibenclamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505996/),[ng] / [ml],408.17,32634,DB01016,Glyburide
,2505996,areas under the blood concentration-time curves (AUC0-infinity),"The areas under the blood concentration-time curves (AUC0-infinity), with or without antacid, were 408.17 +/- 168.25 and 307.9 +/- 84.13 ng/ml (p less than 0.05), respectively.",Influence of antacids on the bioavailability of glibenclamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505996/),[ng] / [ml],307.9,32635,DB01016,Glyburide
,2505996,peak concentrations,"The peak concentrations of 96.88 +/- 49.9 and 66.19 +/- 32.35 ng/ml/h (p less than 0.05) with or without antacid, were reached in 4.13 and 3.81 h, respectively.",Influence of antacids on the bioavailability of glibenclamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505996/),[ng] / [h·ml],96.88,32636,DB01016,Glyburide
,2505996,peak concentrations,"The peak concentrations of 96.88 +/- 49.9 and 66.19 +/- 32.35 ng/ml/h (p less than 0.05) with or without antacid, were reached in 4.13 and 3.81 h, respectively.",Influence of antacids on the bioavailability of glibenclamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505996/),[ng] / [h·ml],66.19,32637,DB01016,Glyburide
,3104218,peak value,"Plasma glibenclamide levels rose faster, the peak value was higher (637 +/- 154 versus 411 +/- 76 nmol/l, p less than 0.05) and the area under the curve from 0 to 240 min was 35% greater (p less than 0.05) on HB420 than on HB419.","Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104218/),[nM] / [l],637,39876,DB01016,Glyburide
,3104218,peak value,"Plasma glibenclamide levels rose faster, the peak value was higher (637 +/- 154 versus 411 +/- 76 nmol/l, p less than 0.05) and the area under the curve from 0 to 240 min was 35% greater (p less than 0.05) on HB420 than on HB419.","Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104218/),[nM] / [l],411,39877,DB01016,Glyburide
,6811355,minimum level of detection,The calibration curve of the assay was linear over the range 10-500 microgram/l and the minimum level of detection was 2 microgram/l.,Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811355/),[μg] / [l],2,41411,DB01016,Glyburide
,6811355,half-life,The mean half-life was found to be 1.47 +/- 0.42 h (SD) and no evidence for a non-linear beta-phase or slowly equilibrating 'deep' compartment was found although this could not be rigorously excluded.,Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811355/),h,1.47,41412,DB01016,Glyburide
,6811355,systemic drug clearance,The mean systemic drug clearance was 78 +/- 29 ml X h-1 X kg-1 and the apparent volume of distribution in the beta-phase was 155 +/- 44 ml/kg.,Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811355/),[ml] / [h·kg],78,41413,DB01016,Glyburide
,6811355,apparent volume of distribution in the beta-phase,The mean systemic drug clearance was 78 +/- 29 ml X h-1 X kg-1 and the apparent volume of distribution in the beta-phase was 155 +/- 44 ml/kg.,Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811355/),[ml] / [kg],155,41414,DB01016,Glyburide
,6811355,time of maximum response,The median time of maximum response of plasma immunoreactive insulin was 25 min and the median time of maximum blood glucose response was 53 min.,Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811355/),min,25,41415,DB01016,Glyburide
,6811355,time of maximum blood glucose response,The median time of maximum response of plasma immunoreactive insulin was 25 min and the median time of maximum blood glucose response was 53 min.,Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811355/),min,53,41416,DB01016,Glyburide
,3935463,areas under the curve,"The means of the areas under the curve were 477 +/- 131 ng . h ml-1 for the stomach, 475 +/- 142 ng . h ml-1 for the duodenum and 486 +/- 301 ng . h ml-1 for the colon.",Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),[h·ng] / [ml],477,42570,DB01016,Glyburide
,3935463,areas under the curve,"The means of the areas under the curve were 477 +/- 131 ng . h ml-1 for the stomach, 475 +/- 142 ng . h ml-1 for the duodenum and 486 +/- 301 ng . h ml-1 for the colon.",Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),[h·ng] / [ml],475,42571,DB01016,Glyburide
,3935463,areas under the curve,"The means of the areas under the curve were 477 +/- 131 ng . h ml-1 for the stomach, 475 +/- 142 ng . h ml-1 for the duodenum and 486 +/- 301 ng . h ml-1 for the colon.",Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),[h·ng] / [ml],486,42572,DB01016,Glyburide
,3935463,mean residence time,The mean residence time changed from 2.67 +/- 0.35 h for the stomach to 2.42 +/- 0.48 h for the duodenum and 3.55 +/- 0.68 h for the colon.,Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),h,2.67,42573,DB01016,Glyburide
,3935463,mean residence time,The mean residence time changed from 2.67 +/- 0.35 h for the stomach to 2.42 +/- 0.48 h for the duodenum and 3.55 +/- 0.68 h for the colon.,Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),h,2.42,42574,DB01016,Glyburide
,3935463,mean residence time,The mean residence time changed from 2.67 +/- 0.35 h for the stomach to 2.42 +/- 0.48 h for the duodenum and 3.55 +/- 0.68 h for the colon.,Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),h,3.55,42575,DB01016,Glyburide
,3935463,pK,"Since glibenclamide--a weak acid--has a pK-value of about 6.5, these data seem to confirm the pH-partition hypothesis of drug absorption.",Absorption of glibenclamide from different sites of the gastro-intestinal tract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935463/),,6.5,42576,DB01016,Glyburide
,11553186,C(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),[pM] / [l],971,47820,DB01016,Glyburide
,11553186,C(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),[pM] / [l],659,47821,DB01016,Glyburide
,11553186,T(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),min,46.9,47822,DB01016,Glyburide
,11553186,T(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),min,94.7,47823,DB01016,Glyburide
,30936692,redispersibility indices,"Studies of redispersibility showed considerable preservation of size characteristics of GBD nanocrystals during downstream processing with redispersibility indices of 105 and 118 for GBD-LAC and GBD-MCC, respectively.","Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30936692/),,105,56019,DB01016,Glyburide
,30936692,redispersibility indices,"Studies of redispersibility showed considerable preservation of size characteristics of GBD nanocrystals during downstream processing with redispersibility indices of 105 and 118 for GBD-LAC and GBD-MCC, respectively.","Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30936692/),,118,56020,DB01016,Glyburide
,11466177,flow rate,"The internal standard and glyburide eluted at about 6.7 and 9.6 min, respectively at the flow rate of 1 mL/min.",A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),[ml] / [min],1,64264,DB01016,Glyburide
,11466177,absolute recovery,The absolute recovery ranged from 94.32 to 98.12% and the relative recovery ranged from 91.12 to 97.15%.,A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),%,94.32 to 98.12,64265,DB01016,Glyburide
,11466177,relative recovery,The absolute recovery ranged from 94.32 to 98.12% and the relative recovery ranged from 91.12 to 97.15%.,A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),%,91.12 to 97.15,64266,DB01016,Glyburide
,9117089,Ki,"The Ki value was 4.34 +/- 0.04 x 10(7) M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide.","Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117089/),M,4.34,68040,DB01016,Glyburide
,11406737,elimination half-life,The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin.,Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,2.0,69073,DB01016,Glyburide
,11406737,elimination half-life,The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin.,Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,1.7,69074,DB01016,Glyburide
,11406737,half-life,"In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01).",Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,3.0,69075,DB01016,Glyburide
,11406737,half-life,"In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01).",Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,1.9,69076,DB01016,Glyburide
,9186077,half-life,Glyburide half-life averaged 3.3 hours in control subjects and 5.0 hours in hemodialysis subjects.,Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186077/),h,3.3,69928,DB01016,Glyburide
,9186077,half-life,Glyburide half-life averaged 3.3 hours in control subjects and 5.0 hours in hemodialysis subjects.,Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186077/),h,5.0,69929,DB01016,Glyburide
,34400867,Cmax,"The Cmax and tmax after oral dose of Gb in normal rats were 340.10 µg/ml and 3.67 h, respectively.",Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34400867/),[μg] / [ml],340.10,73474,DB01016,Glyburide
,34400867,tmax,"The Cmax and tmax after oral dose of Gb in normal rats were 340.10 µg/ml and 3.67 h, respectively.",Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34400867/),h,3.67,73475,DB01016,Glyburide
,34400867,Cmax,"Whereas, the Cmax and tmax after oral dose of Gb in HL rats were noted as 773.39 µg/ml and 2.50 h respectively.",Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34400867/),[μg] / [ml],773.39,73476,DB01016,Glyburide
,34400867,tmax,"Whereas, the Cmax and tmax after oral dose of Gb in HL rats were noted as 773.39 µg/ml and 2.50 h respectively.",Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34400867/),h,2.50,73477,DB01016,Glyburide
,34400867,plasma clearance (CL),While the plasma clearance (CL) after oral dose of Gb was 2.53 ml/h and 1.39 ml/h in normal and HL rats respectively.,Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34400867/),[ml] / [h],2.53,73478,DB01016,Glyburide
,34400867,plasma clearance (CL),While the plasma clearance (CL) after oral dose of Gb was 2.53 ml/h and 1.39 ml/h in normal and HL rats respectively.,Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34400867/),[ml] / [h],1.39,73479,DB01016,Glyburide
,15568889,absolute bioavailability,The absolute bioavailability is about 50%.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),%,50,73755,DB01016,Glyburide
,15568889,volume of distribution,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),l,30,73756,DB01016,Glyburide
,15568889,clearance,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),[l] / [h],17,73757,DB01016,Glyburide
,15568889,terminal half-life,The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),h,5.4,73758,DB01016,Glyburide
,8112376,elimination rate constant (lambda z),"The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group.",The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112376/),1/[h],0.08,74250,DB01016,Glyburide
,8112376,clearance (CL),"The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group.",The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112376/),[l] / [h],3.3,74251,DB01016,Glyburide
,8112376,clearance (CL),"The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group.",The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112376/),1/[h],0.07,74252,DB01016,Glyburide
,8112376,clearance (CL),"The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group.",The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112376/),[l] / [h],3.1,74253,DB01016,Glyburide
,8112376,apparent volume of distribution (Vz),"The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group.",The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112376/),l,47.0,74254,DB01016,Glyburide
,8112376,apparent volume of distribution (Vz),"The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group.",The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112376/),l,56.8,74255,DB01016,Glyburide
,2116159,half-lives,"3. The time course of glibenclamide kinetics after 20 mg dosing was adequately described by a two-compartment open model, yielding mean half-lives of 3.3 +/- 1.5 h (t1/2, lambda 1) and 9.7 +/- 1.2 (t1/2, z) for the initial and terminal elimination phases respectively.",Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116159/),h,3.3,75412,DB01016,Glyburide
,2116159,"t1/2, z","3. The time course of glibenclamide kinetics after 20 mg dosing was adequately described by a two-compartment open model, yielding mean half-lives of 3.3 +/- 1.5 h (t1/2, lambda 1) and 9.7 +/- 1.2 (t1/2, z) for the initial and terminal elimination phases respectively.",Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116159/),,9.7,75413,DB01016,Glyburide
,8894500,Tmax,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),min,34,76953,DB01016,Glyburide
,8894500,Tmax,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),min,18,76954,DB01016,Glyburide
,8894500,T1/2,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),h,0.64,76955,DB01016,Glyburide
,8894500,T1/2,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),h,0.98,76956,DB01016,Glyburide
,9016325,oral bioavailability,"With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.",Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9016325/),%,47,77045,DB01016,Glyburide
,9016325,plasma elimination half-life,"With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.",Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9016325/),h,3,77046,DB01016,Glyburide
,6414955,relative bioavailability,It is concluded that Derocytl is not bioequivalent to Euglucon: its relative bioavailability is only 62.5% (AUC0-24).,"Bioavailability and pharmacodynamics of a sustained-release glibenclamide product (Deroctyl) in comparison to a standard tablet formulation (Euglucon, Daonil). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414955/),%,62.5,79534,DB01016,Glyburide
,2515159,peak serum concentrations,"The two products were not found to be significantly different with respect to peak serum concentrations (187.9 +/- 13.3 and 167.6 +/- 9.1 ng.ml-1 for A and B, respectively) or to the corresponding peak times (4.2 +/- 0.2 and 4.1 +/- 0.2 h for A and B, respectively).",Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515159/),[ng] / [ml],187.9,83361,DB01016,Glyburide
,2515159,peak serum concentrations,"The two products were not found to be significantly different with respect to peak serum concentrations (187.9 +/- 13.3 and 167.6 +/- 9.1 ng.ml-1 for A and B, respectively) or to the corresponding peak times (4.2 +/- 0.2 and 4.1 +/- 0.2 h for A and B, respectively).",Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515159/),[ng] / [ml],167.6,83362,DB01016,Glyburide
,2515159,peak times,"The two products were not found to be significantly different with respect to peak serum concentrations (187.9 +/- 13.3 and 167.6 +/- 9.1 ng.ml-1 for A and B, respectively) or to the corresponding peak times (4.2 +/- 0.2 and 4.1 +/- 0.2 h for A and B, respectively).",Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515159/),h,4.2,83363,DB01016,Glyburide
,2515159,peak times,"The two products were not found to be significantly different with respect to peak serum concentrations (187.9 +/- 13.3 and 167.6 +/- 9.1 ng.ml-1 for A and B, respectively) or to the corresponding peak times (4.2 +/- 0.2 and 4.1 +/- 0.2 h for A and B, respectively).",Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515159/),h,4.1,83364,DB01016,Glyburide
,2515159,area under serum concentration-time curve,"Furthermore, the two products were not found significantly different in the extent of absorption as indicated by the area under serum concentration-time curve (1,118.0 +/- 86.7 and 986.5 +/- 75.1 ng.h.ml-1 for A and B, respectively).",Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515159/),[h·ng] / [ml],"1,118.0",83365,DB01016,Glyburide
,2515159,area under serum concentration-time curve,"Furthermore, the two products were not found significantly different in the extent of absorption as indicated by the area under serum concentration-time curve (1,118.0 +/- 86.7 and 986.5 +/- 75.1 ng.h.ml-1 for A and B, respectively).",Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515159/),[h·ng] / [ml],986.5,83366,DB01016,Glyburide
,12475773,half-life (t(1/2)),"We demonstrate that the half-life (t(1/2)) of glibenclamide in the blood is increased in Hnf-1alpha(-/-) mice compared with wild-type littermates (3.9 +/- 1.3 vs. 1.5 +/- 1.8 min, P <or= 0.05).","Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12475773/),min,3.9,84408,DB01016,Glyburide
,12475773,half-life (t(1/2)),"We demonstrate that the half-life (t(1/2)) of glibenclamide in the blood is increased in Hnf-1alpha(-/-) mice compared with wild-type littermates (3.9 +/- 1.3 vs. 1.5 +/- 1.8 min, P <or= 0.05).","Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12475773/),min,1.5,84409,DB01016,Glyburide
,2503528,flow rate,"After centrifugation, separation and reconstitution, the redissolved residue was eluted from 5 mu Spherisorb C-8 reversed phase column at ambient temperature using a mobile phase consisting of acetonitrile-water (45:55 v/v) at pH 3.7-3.8 and pumped at a flow rate 2 ml/min.",A rapid high-performance liquid chromatography assay of glibenclamide in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503528/),[ml] / [min],2,85158,DB01016,Glyburide
no longer,2503528,analysis time,The analysis time was no longer than 12 min.,A rapid high-performance liquid chromatography assay of glibenclamide in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503528/),min,12,85159,DB01016,Glyburide
,2503528,detection limit,The detection limit of glibenclamide in serum was 20 ng/ml.,A rapid high-performance liquid chromatography assay of glibenclamide in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503528/),[ng] / [ml],20,85160,DB01016,Glyburide
,2503528,recovery,The mean recovery of drug from serum samples spiked with known amounts of glibenclamide was 96.77%.,A rapid high-performance liquid chromatography assay of glibenclamide in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503528/),%,96.77,85161,DB01016,Glyburide
,15018802,total run time,The method has a chromatographic total run time of 3.4 min and was linear within the range 2-2000 ng/ml.,Rapid determination of metformin in human plasma by liquid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018802/),min,3.4,95814,DB01016,Glyburide
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],43.1,102014,DB01016,Glyburide
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],45.9,102015,DB01016,Glyburide
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],29.0,102016,DB01016,Glyburide
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],33.1,102017,DB01016,Glyburide
,29777569,clearance (CL,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),1/[h·kg·l],0.23,104632,DB01016,Glyburide
,29777569,maximum concentration (Cmax,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),[μg] / [l],5907.47,104633,DB01016,Glyburide
,29777569,half-life (T1/2,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),h,3.50,104634,DB01016,Glyburide
,29503767,apparent elimination half-life,"Peak serum concentrations of glyburide were attained at a mean of 13 h after dosing, and mean apparent elimination half-life was approximately 7 h.",Pharmacokinetics and safety of oral glyburide in dogs with acute spinal cord injury. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29503767/),h,7,107618,DB01016,Glyburide
,29503767,maximum plasma concentration,Observed mean maximum plasma concentration was 31 ng/mL.,Pharmacokinetics and safety of oral glyburide in dogs with acute spinal cord injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29503767/),[ng] / [ml],31,107619,DB01016,Glyburide
,8061850,terminal half-life,"After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes.",Spirapril: pharmacokinetic properties and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),min,20-50,108588,DB01016,Glyburide
,8061850,Plasma clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],56,108589,DB01016,Glyburide
,8061850,renal clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],11,108590,DB01016,Glyburide
,8061850,volume of distribution,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,28,108591,DB01016,Glyburide
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,2,108592,DB01016,Glyburide
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,35,108593,DB01016,Glyburide
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],10,108594,DB01016,Glyburide
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],7.6,108595,DB01016,Glyburide
,8061850,volume of distribution,The volume of distribution was 43 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,43,108596,DB01016,Glyburide
,8061850,bioavailability,The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero.,Spirapril: pharmacokinetic properties and drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),%,50,108597,DB01016,Glyburide
,9146849,steady-state serum concentration,"An increase in the steady-state serum concentration when the effect is 50% of maximal, CEss50, was found in the sequence M1 (23 ng ml-1), M2 (37 ng ml-1) and Gb (108 ng ml-1).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),[ng] / [ml],23,111637,DB01016,Glyburide
,9146849,steady-state serum concentration,"An increase in the steady-state serum concentration when the effect is 50% of maximal, CEss50, was found in the sequence M1 (23 ng ml-1), M2 (37 ng ml-1) and Gb (108 ng ml-1).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),[ng] / [ml],37,111638,DB01016,Glyburide
,9146849,steady-state serum concentration,"An increase in the steady-state serum concentration when the effect is 50% of maximal, CEss50, was found in the sequence M1 (23 ng ml-1), M2 (37 ng ml-1) and Gb (108 ng ml-1).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),[ng] / [ml],108,111639,DB01016,Glyburide
,9146849,elimination rate constants from the effect site (,"The elimination rate constants from the effect site (kEO) were estimated and increased in the order M1 (0.178 h-1, CV 13%), M2 (0.479 h-1, CV 8.5%) and Gb (1.59 h-1, CV 36%).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),1/[h],0.178,111640,DB01016,Glyburide
,9146849,kEO),"The elimination rate constants from the effect site (kEO) were estimated and increased in the order M1 (0.178 h-1, CV 13%), M2 (0.479 h-1, CV 8.5%) and Gb (1.59 h-1, CV 36%).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),1/[h],0.178,111641,DB01016,Glyburide
,9146849,kEO),"The elimination rate constants from the effect site (kEO) were estimated and increased in the order M1 (0.178 h-1, CV 13%), M2 (0.479 h-1, CV 8.5%) and Gb (1.59 h-1, CV 36%).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),1/[h],0.479,111642,DB01016,Glyburide
,9146849,kEO),"The elimination rate constants from the effect site (kEO) were estimated and increased in the order M1 (0.178 h-1, CV 13%), M2 (0.479 h-1, CV 8.5%) and Gb (1.59 h-1, CV 36%).",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),1/[h],1.59,111643,DB01016,Glyburide
,9146849,half-lives,"Corresponding equilibration half-lives for the effect site (kEO-HL) were 3.9 h, 1.4 h and 0.44 h.",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),h,3.9,111644,DB01016,Glyburide
,9146849,half-lives,"Corresponding equilibration half-lives for the effect site (kEO-HL) were 3.9 h, 1.4 h and 0.44 h.",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),h,1.4,111645,DB01016,Glyburide
,9146849,half-lives,"Corresponding equilibration half-lives for the effect site (kEO-HL) were 3.9 h, 1.4 h and 0.44 h.",Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9146849/),h,0.44,111646,DB01016,Glyburide
,18605232,Cmax,"Pharmacokinetic parameters were obtained and values (mean +/- S.E.M.) were as follows: Cmax 273.32 +/- 25.84 versus 294.83 +/- 27.12 ng/ml; tmax 3.03 +/- 0.23 versus 2.87 +/- 0.24 h; and AUC24h 1396.66 +/- 130.18 versus 1557.99 +/- 140.24 ng x h/ml, for Daonil and Gen-Glybe tablets, respectively.",Bioequivalence of two oral formulations of glyburide (glibenclamide). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605232/),[ng] / [ml],273.32,127938,DB01016,Glyburide
,18605232,Cmax,"Pharmacokinetic parameters were obtained and values (mean +/- S.E.M.) were as follows: Cmax 273.32 +/- 25.84 versus 294.83 +/- 27.12 ng/ml; tmax 3.03 +/- 0.23 versus 2.87 +/- 0.24 h; and AUC24h 1396.66 +/- 130.18 versus 1557.99 +/- 140.24 ng x h/ml, for Daonil and Gen-Glybe tablets, respectively.",Bioequivalence of two oral formulations of glyburide (glibenclamide). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605232/),[ng] / [ml],294.83,127939,DB01016,Glyburide
,18605232,tmax,"Pharmacokinetic parameters were obtained and values (mean +/- S.E.M.) were as follows: Cmax 273.32 +/- 25.84 versus 294.83 +/- 27.12 ng/ml; tmax 3.03 +/- 0.23 versus 2.87 +/- 0.24 h; and AUC24h 1396.66 +/- 130.18 versus 1557.99 +/- 140.24 ng x h/ml, for Daonil and Gen-Glybe tablets, respectively.",Bioequivalence of two oral formulations of glyburide (glibenclamide). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605232/),h,3.03,127940,DB01016,Glyburide
,18605232,tmax,"Pharmacokinetic parameters were obtained and values (mean +/- S.E.M.) were as follows: Cmax 273.32 +/- 25.84 versus 294.83 +/- 27.12 ng/ml; tmax 3.03 +/- 0.23 versus 2.87 +/- 0.24 h; and AUC24h 1396.66 +/- 130.18 versus 1557.99 +/- 140.24 ng x h/ml, for Daonil and Gen-Glybe tablets, respectively.",Bioequivalence of two oral formulations of glyburide (glibenclamide). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605232/),h,2.87,127941,DB01016,Glyburide
,18605232,AUC24h,"Pharmacokinetic parameters were obtained and values (mean +/- S.E.M.) were as follows: Cmax 273.32 +/- 25.84 versus 294.83 +/- 27.12 ng/ml; tmax 3.03 +/- 0.23 versus 2.87 +/- 0.24 h; and AUC24h 1396.66 +/- 130.18 versus 1557.99 +/- 140.24 ng x h/ml, for Daonil and Gen-Glybe tablets, respectively.",Bioequivalence of two oral formulations of glyburide (glibenclamide). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605232/),[h·ng] / [ml],1396.66,127942,DB01016,Glyburide
,18605232,AUC24h,"Pharmacokinetic parameters were obtained and values (mean +/- S.E.M.) were as follows: Cmax 273.32 +/- 25.84 versus 294.83 +/- 27.12 ng/ml; tmax 3.03 +/- 0.23 versus 2.87 +/- 0.24 h; and AUC24h 1396.66 +/- 130.18 versus 1557.99 +/- 140.24 ng x h/ml, for Daonil and Gen-Glybe tablets, respectively.",Bioequivalence of two oral formulations of glyburide (glibenclamide). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18605232/),[h·ng] / [ml],1557.99,127943,DB01016,Glyburide
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB01016,Glyburide
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB01016,Glyburide
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB01016,Glyburide
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB01016,Glyburide
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB01016,Glyburide
up to,3937815,peak plasma glibenclamide concentrations,The HB 420 glibenclamide preparations induced peak plasma glibenclamide concentrations up to about 90 ng/ml at 1.3 to 1.4 hours after ingestion.,The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937815/),[ng] / [ml],90,130951,DB01016,Glyburide
,3937815,elimination half-life,The mean elimination half-life of glibenclamide was 1.3 +/- 0.1 hours in the case of both HB 420 preparations and 2.0 to 2.5 +/- 0.2 hours in the case of HB 419 preparations.,The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937815/),h,1.3,130952,DB01016,Glyburide
,3937815,elimination half-life,The mean elimination half-life of glibenclamide was 1.3 +/- 0.1 hours in the case of both HB 420 preparations and 2.0 to 2.5 +/- 0.2 hours in the case of HB 419 preparations.,The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937815/),h,2.0 to 2.,130953,DB01016,Glyburide
,25910045,flow rate,The chromatographic separation was performed on a C18 column with acetonitrile and 0.1% formic acid water as mobile phase and with gradient elution at a flow rate of 0.2 mL/min.,Simultaneous determination of doxorubicin and curcumin in rat plasma by LC-MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25910045/),[ml] / [min],0.2,132387,DB01016,Glyburide
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB01016,Glyburide
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB01016,Glyburide
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB01016,Glyburide
,21182938,clearance,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),[l] / [h],27.83,139576,DB01016,Glyburide
,21182938,peak plasma concentration,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),[μg] / [ml],18.39,139577,DB01016,Glyburide
,21182938,area under the plasma concentration time curve,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),[μg] / [h·ml],120.02,139578,DB01016,Glyburide
,21182938,elimination half-life,"In co-treated group, the pharmacokinetic parameters like clearance (27.83±3.55l/h) of glyburide was reduced, while peak plasma concentration (18.39±5.29μg/ml), area under the plasma concentration time curve (120.02±15.17μg/ml/h) and elimination half-life (4.09±0.50h) were significantly increased when compared to glyburide alone administered rats.",Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182938/),h,4.09,139579,DB01016,Glyburide
<,9463023,action period,"The action period for ""short-term"" sulfonamides is < or = 24 h (tolbutamide, glipizide) and can exceed 24 h for ""long-term"" sulfonamides (e.g. glibenclamide).","[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463023/),h,24,140609,DB01016,Glyburide
exceed,9463023,action period,"The action period for ""short-term"" sulfonamides is < or = 24 h (tolbutamide, glipizide) and can exceed 24 h for ""long-term"" sulfonamides (e.g. glibenclamide).","[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463023/),h,24,140610,DB01016,Glyburide
,22853867,relative AUC0-12 ratio,The relative AUC0-12 ratio of lansoprazole in EMs and PMs was 1:3.3 - 4.3.,Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22853867/),,1,142475,DB01016,Glyburide
,16342679,C(max),"After a single oral dose of 2.5 mg glibenclamide, C(max) was (70.0 +/- 11.5) microg x L(-1) in CYP2C9 * 1/ * 3 subjects and (51.9 +/- 12.3) microg x L(-1) in * 1/ *1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[μg] / [l],70.0,145409,DB01016,Glyburide
,16342679,C(max),"After a single oral dose of 2.5 mg glibenclamide, C(max) was (70.0 +/- 11.5) microg x L(-1) in CYP2C9 * 1/ * 3 subjects and (51.9 +/- 12.3) microg x L(-1) in * 1/ *1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[μg] / [l],51.9,145410,DB01016,Glyburide
,16342679,AUC(0-infinity),"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·μg] / [l],435,145411,DB01016,Glyburide
,16342679,AUC(0-infinity),"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·μg] / [l],287,145412,DB01016,Glyburide
,16342679,CL/F,"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],96,145413,DB01016,Glyburide
,16342679,CL/F,"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],160,145414,DB01016,Glyburide
,16342679,C(max),"After a single oral dose of 8 mg lornoxicam, C(max) was (1.54 +/- 0.24) mg x L(-1) in CYP2C9 * 1/ * 3 subjects and (1.19 +/- 0.37) mg x L(-1) in * 1/ * 1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[mg] / [l],1.54,145415,DB01016,Glyburide
,16342679,C(max),"After a single oral dose of 8 mg lornoxicam, C(max) was (1.54 +/- 0.24) mg x L(-1) in CYP2C9 * 1/ * 3 subjects and (1.19 +/- 0.37) mg x L(-1) in * 1/ * 1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[mg] / [l],1.19,145416,DB01016,Glyburide
,16342679,AUC(o-infinity,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·mg] / [l],14.9,145417,DB01016,Glyburide
,16342679,AUC(o-infinity,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·mg] / [l],6.92,145418,DB01016,Glyburide
,16342679,CL/F,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],9.1,145419,DB01016,Glyburide
,16342679,CL/F,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],20.1,145420,DB01016,Glyburide
,26446475,half-life,"The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively.",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,3.8,146051,DB01016,Glyburide
,26446475,half-life,"The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively.",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,3.7,146052,DB01016,Glyburide
,26446475,t1/2,"The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively).",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,9.5,146053,DB01016,Glyburide
,26446475,t1/2,"The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively).",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,5.0,146054,DB01016,Glyburide
,19295505,concentration ratio,The average umbilical cord/maternal plasma glyburide concentration ratio at the time of delivery was 0.7 +/- 0.4.,Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19295505/),,0.7,146720,DB01016,Glyburide
,7758252,time to achieve maximal systemic concentrations (tmax,"The pharmacokinetics of dipyrone are characterised by rapid hydrolysis to the active moiety 4-methyl-amino-antipyrine (MAA), which has 85% bioavailability after oral administration in tablet form, and takes a short time to achieve maximal systemic concentrations (tmax of 1.2 to 2.0 hours).",Clinical pharmacokinetics of dipyrone and its metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,1.2 to 2.0,151448,DB01016,Glyburide
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,87,151449,DB01016,Glyburide
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,54,151450,DB01016,Glyburide
,7758252,elimination half-life (t1/2),"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,2.6 to 3.5,151451,DB01016,Glyburide
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,3.8,151452,DB01016,Glyburide
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,5.5,151453,DB01016,Glyburide
less,7758252,Protein binding,Protein binding of the 4 main metabolites is less than 60%.,Clinical pharmacokinetics of dipyrone and its metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,60,151454,DB01016,Glyburide
,7758252,volume of distribution,The volume of distribution of MAA is about 1.15 L/kg of lean body mass.,Clinical pharmacokinetics of dipyrone and its metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),[l] / [kg],1.15,151455,DB01016,Glyburide
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],6.9,152383,DB01016,Glyburide
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],10.4,152384,DB01016,Glyburide
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],11.9,152385,DB01016,Glyburide
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],2.4,152386,DB01016,Glyburide
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.3,152387,DB01016,Glyburide
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.0,152388,DB01016,Glyburide
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],13.9,152389,DB01016,Glyburide
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],6.6,152390,DB01016,Glyburide
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.9,152391,DB01016,Glyburide
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],7.2,152392,DB01016,Glyburide
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],1.5,152393,DB01016,Glyburide
,3932228,absolute bioavailability,A comparison of the dose-corrected areas under the concentration-time curves yielded an absolute bioavailability of 102% for HB 420.,Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932228/),%,102,154428,DB01016,Glyburide
,3932228,relative bioavailability,The relative bioavailability of HB 419 to HB 420 was 73%.,Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932228/),%,73,154429,DB01016,Glyburide
,3932228,terminal elimination half-life,"The median for the terminal elimination half-life for glibenclamide was 1.38 hours (min. 0.65, max. 4.64 hours), the total clearance was 100 ml/min and the steady-state distribution volume was 7.3 l (0.1 l/kg).",Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932228/),h,1.38,154430,DB01016,Glyburide
,3932228,total clearance,"The median for the terminal elimination half-life for glibenclamide was 1.38 hours (min. 0.65, max. 4.64 hours), the total clearance was 100 ml/min and the steady-state distribution volume was 7.3 l (0.1 l/kg).",Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932228/),[ml] / [min],100,154431,DB01016,Glyburide
,3932228,steady-state distribution volume,"The median for the terminal elimination half-life for glibenclamide was 1.38 hours (min. 0.65, max. 4.64 hours), the total clearance was 100 ml/min and the steady-state distribution volume was 7.3 l (0.1 l/kg).",Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932228/),l,7.3,154432,DB01016,Glyburide
,3081293,plasma t1/2,"Patients with normal to moderately impaired renal function (creatinine clearance [CLCR] of 29 to 131 ml/min/1.7 m2) had glyburide plasma t1/2 values of 2.0 to 5.0 hours, with no relationship between CLCR and glyburide clearance.",Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081293/),h,2.0 to 5.0,159022,DB01016,Glyburide
,3081293,t1/2,One subject with severe renal impairment (CLCR = 5 ml/min/1.7 m2) had decreased glyburide clearance that resulted in a t1/2 of 11 hours.,Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081293/),h,11,159023,DB01016,Glyburide
,16198656,area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity),Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721).,"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198656/),[h·μg] / [ml],0.46,166060,DB01016,Glyburide
,16198656,elimination half-life (t1/2),Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721).,"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198656/),h,2.09,166061,DB01016,Glyburide
,16198656,elimination half-life (t1/2),Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721).,"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198656/),h,2.24,166062,DB01016,Glyburide
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],973,167821,DB01016,Glyburide
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],710,167822,DB01016,Glyburide
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],726,167823,DB01016,Glyburide
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],8.25,167824,DB01016,Glyburide
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],6.0,167825,DB01016,Glyburide
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],7.97,167826,DB01016,Glyburide
,3111514,glucose,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],237,167827,DB01016,Glyburide
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],237,167828,DB01016,Glyburide
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],228,167829,DB01016,Glyburide
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],195,167830,DB01016,Glyburide
,23418678,m/z,"The MS/MS transitions were m/z 304.1 → 161.1 for evodiamine, m/z 471.2 → 425.1 for evodine, and m/z 494.1 → 369.1 for IS.",Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),,304.1,168207,DB01016,Glyburide
,23418678,m/z,"The MS/MS transitions were m/z 304.1 → 161.1 for evodiamine, m/z 471.2 → 425.1 for evodine, and m/z 494.1 → 369.1 for IS.",Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),,161.1,168208,DB01016,Glyburide
,23418678,m/z,"The MS/MS transitions were m/z 304.1 → 161.1 for evodiamine, m/z 471.2 → 425.1 for evodine, and m/z 494.1 → 369.1 for IS.",Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),,471.2,168209,DB01016,Glyburide
,23418678,m/z,"The MS/MS transitions were m/z 304.1 → 161.1 for evodiamine, m/z 471.2 → 425.1 for evodine, and m/z 494.1 → 369.1 for IS.",Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),,425.1,168210,DB01016,Glyburide
,23418678,m/z,"The MS/MS transitions were m/z 304.1 → 161.1 for evodiamine, m/z 471.2 → 425.1 for evodine, and m/z 494.1 → 369.1 for IS.",Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),,494.1,168211,DB01016,Glyburide
,23418678,m/z,"The MS/MS transitions were m/z 304.1 → 161.1 for evodiamine, m/z 471.2 → 425.1 for evodine, and m/z 494.1 → 369.1 for IS.",Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),,369.1,168212,DB01016,Glyburide
,23418678,extraction recoveries,The mean extraction recoveries were 88.10 ± 3.21% for evodiamine and 81.24 ± 4.07% for evodine.,Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),%,88.10,168213,DB01016,Glyburide
,23418678,extraction recoveries,The mean extraction recoveries were 88.10 ± 3.21% for evodiamine and 81.24 ± 4.07% for evodine.,Simultaneous determination of evodiamine and evodine in Beagle dog plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23418678/),%,81.24,168214,DB01016,Glyburide
,2515863,terminal phase half-life,"The terminal phase half-life of glibenclamide was 2.46 +/- 0.67 h (mean +/- SD), total drug clearance was 48.7 +/- 11.0 ml.min-1 and the slow disposition phase rate constant was 0.30 +/- 0.08 h-1.",Uniform elimination pattern for glibenclamide in healthy Caucasian males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515863/),h,2.46,177791,DB01016,Glyburide
,2515863,total drug clearance,"The terminal phase half-life of glibenclamide was 2.46 +/- 0.67 h (mean +/- SD), total drug clearance was 48.7 +/- 11.0 ml.min-1 and the slow disposition phase rate constant was 0.30 +/- 0.08 h-1.",Uniform elimination pattern for glibenclamide in healthy Caucasian males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515863/),[ml] / [min],48.7,177792,DB01016,Glyburide
,2515863,slow disposition phase rate constant,"The terminal phase half-life of glibenclamide was 2.46 +/- 0.67 h (mean +/- SD), total drug clearance was 48.7 +/- 11.0 ml.min-1 and the slow disposition phase rate constant was 0.30 +/- 0.08 h-1.",Uniform elimination pattern for glibenclamide in healthy Caucasian males. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515863/),1/[h],0.30,177793,DB01016,Glyburide
,16781839,plasma extraction recovery,The mean plasma extraction recovery of indapamide was 90.5-93.9%.,A sensitive LC-ESI-MS method for the determination of indapamide in human plasma: method and clinical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16781839/),%,90.5-93.9,179363,DB01016,Glyburide
,28364197,AUC (0-36 h),"Further reduction from 312.5 to 237.6 nm lead to a significant increase (p < 0.001) of the AUC (0-36 h) from 6857.8 ± 369.3 ng mL-1 h to 12,928.3 ± 1591.4 ng mL-1 h, respectively, in rats.",The role of particle size of glyburide crystals in improving its oral absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28364197/),[h·ng] / [ml],6857.8,179366,DB01016,Glyburide
,28364197,AUC (0-36 h),"Further reduction from 312.5 to 237.6 nm lead to a significant increase (p < 0.001) of the AUC (0-36 h) from 6857.8 ± 369.3 ng mL-1 h to 12,928.3 ± 1591.4 ng mL-1 h, respectively, in rats.",The role of particle size of glyburide crystals in improving its oral absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28364197/),[h·ng] / [ml],"12,928.3",179367,DB01016,Glyburide
,24839071,Active hepatic uptake,"Active hepatic uptake was found to be significantly higher than the passive uptake clearance (15.8 versus 5.3 μL/min/10(6)-hepatocytes), using the sandwich-cultured hepatocyte model.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),[min·μl] / [10(6],15.8,179669,DB01016,Glyburide
,24839071,passive uptake clearance,"Active hepatic uptake was found to be significantly higher than the passive uptake clearance (15.8 versus 5.3 μL/min/10(6)-hepatocytes), using the sandwich-cultured hepatocyte model.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),[min·μl] / [10(6],5.3,179670,DB01016,Glyburide
,24839071,intrinsic clearance,"In vitro, glyburide is metabolized (intrinsic clearance, 52.9 μL/min/mg-microsomal protein) by CYP3A4, CYP2C9, and CYP2C8 with fraction metabolism of 0.53, 0.36, and 0.11, respectively.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),[μl] / [mg-·min],52.9,179671,DB01016,Glyburide
,24839071,fraction metabolism,"In vitro, glyburide is metabolized (intrinsic clearance, 52.9 μL/min/mg-microsomal protein) by CYP3A4, CYP2C9, and CYP2C8 with fraction metabolism of 0.53, 0.36, and 0.11, respectively.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),,0,179672,DB01016,Glyburide
,24699418,Percent drug entrapment,Percent drug entrapment of MH was 99.6±0.35% and in vitro floating ability was 11.3±0.47h.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),%,99.6,183504,DB01016,Glyburide
,24699418,floating ability,Percent drug entrapment of MH was 99.6±0.35% and in vitro floating ability was 11.3±0.47h.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),h,11.3,183505,DB01016,Glyburide
,24699418,en,"While GLB multiparticulates showed entrapment efficiency of 99.8±0.11%, in vitro buoyancy for 11±0.2h and improved solubility and dissolution rate.",Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),%,99.8,183506,DB01016,Glyburide
,24699418,f2,Model independent analysis f2 value for GIV was 40 while for M II was 54.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),,40,183507,DB01016,Glyburide
,24699418,f2,Model independent analysis f2 value for GIV was 40 while for M II was 54.,Studies on biological macromolecules lipid-Gelucire based gastroretentive multiparticulate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24699418/),,54,183508,DB01016,Glyburide
,16023818,C(max),"After intragastric administration of ginkgolide B to beagle dogs, C(max) and T(max) of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h.",Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023818/),[ng] / [ml],43.8,186480,DB01016,Glyburide
,16023818,T(max),"After intragastric administration of ginkgolide B to beagle dogs, C(max) and T(max) of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h.",Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023818/),h,0.5,186481,DB01016,Glyburide
,16023818,elimination half-life (t(1/2)),"After intragastric administration of ginkgolide B to beagle dogs, C(max) and T(max) of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h.",Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16023818/),h,2.85,186482,DB01016,Glyburide
,1902238,time to peak glyburide concentrations (Tmax),"Peak serum glyburide concentrations were increased by 18%, and mean time to peak glyburide concentrations (Tmax) decreased from 4.9 to 3.0 hours during erythromycin treatment; only the difference in Tmax was statistically significant.",Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1902238/),h,4.9,196531,DB01016,Glyburide
,1902238,time to peak glyburide concentrations (Tmax),"Peak serum glyburide concentrations were increased by 18%, and mean time to peak glyburide concentrations (Tmax) decreased from 4.9 to 3.0 hours during erythromycin treatment; only the difference in Tmax was statistically significant.",Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1902238/),h,3.0,196532,DB01016,Glyburide
greater,12008145,Recovery,Recovery for glibenclamide was greater than 91.5% and for internal standard was 93.5%.,A validated high-performance liquid chromatographic method for the determination of glibenclamide in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008145/),%,91.5,198048,DB01016,Glyburide
,12008145,Recovery,Recovery for glibenclamide was greater than 91.5% and for internal standard was 93.5%.,A validated high-performance liquid chromatographic method for the determination of glibenclamide in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008145/),%,93.5,198049,DB01016,Glyburide
,26925503,EE%,"The lecithin-containing GLI-loaded SLN formulation, selected for in vivo studies in virtue of its higher EE% than the PEG-coated formulation (70.3% vs 19.6%), showed a significantly stronger hypoglycemic effect with respect to the drug alone, in terms of both shorter onset time and longer duration of the effect.",Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925503/),%,70.3,199961,DB01016,Glyburide
,26925503,EE%,"The lecithin-containing GLI-loaded SLN formulation, selected for in vivo studies in virtue of its higher EE% than the PEG-coated formulation (70.3% vs 19.6%), showed a significantly stronger hypoglycemic effect with respect to the drug alone, in terms of both shorter onset time and longer duration of the effect.",Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26925503/),%,19.6,199962,DB01016,Glyburide
,9551701,terminal elimination half-life,"We have demonstrated Gb to have a terminal elimination half-life of 15 h, and the main metabolites have a hypoglycaemic effect.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),h,15,205132,DB01016,Glyburide
,9551701,clearance,"Two groups of 11 diabetic patients with impaired renal function (IRF, iohexol clearance range 7-42 ml.min(-1) . 1.73 m(-2)) or normal renal function (NRF, iohexol clearance range 75-140 ml.min(-1) . 1.73 m(-2)) were compared.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[1.73·ml] / [(m)^2·min],7-42,205133,DB01016,Glyburide
,9551701,clearance,"Two groups of 11 diabetic patients with impaired renal function (IRF, iohexol clearance range 7-42 ml.min(-1) . 1.73 m(-2)) or normal renal function (NRF, iohexol clearance range 75-140 ml.min(-1) . 1.73 m(-2)) were compared.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[1.73·ml] / [(m)^2·min],75-140,205134,DB01016,Glyburide
,9551701,Peak serum,"Peak serum values of M1 (24-85 ng.ml(-1) vs 16-57 ng.ml(-1)), M2 (7-22 ng.ml(-1) vs <5-18 ng.ml(-1)) and M1 + M2 (32-100 ng.ml(-1) vs 23-76 ng.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[ng] / [ml],24-85,205135,DB01016,Glyburide
,9551701,Peak serum,"Peak serum values of M1 (24-85 ng.ml(-1) vs 16-57 ng.ml(-1)), M2 (7-22 ng.ml(-1) vs <5-18 ng.ml(-1)) and M1 + M2 (32-100 ng.ml(-1) vs 23-76 ng.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[ng] / [ml],16-57,205136,DB01016,Glyburide
,9551701,Peak serum,"Peak serum values of M1 (24-85 ng.ml(-1) vs 16-57 ng.ml(-1)), M2 (7-22 ng.ml(-1) vs <5-18 ng.ml(-1)) and M1 + M2 (32-100 ng.ml(-1) vs 23-76 ng.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[ng] / [ml],7-22,205137,DB01016,Glyburide
<,9551701,Peak serum,"Peak serum values of M1 (24-85 ng.ml(-1) vs 16-57 ng.ml(-1)), M2 (7-22 ng.ml(-1) vs <5-18 ng.ml(-1)) and M1 + M2 (32-100 ng.ml(-1) vs 23-76 ng.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[ng] / [ml],5-18,205138,DB01016,Glyburide
,9551701,Peak serum,"Peak serum values of M1 (24-85 ng.ml(-1) vs 16-57 ng.ml(-1)), M2 (7-22 ng.ml(-1) vs <5-18 ng.ml(-1)) and M1 + M2 (32-100 ng.ml(-1) vs 23-76 ng.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),[ng] / [ml],32-100,205139,DB01016,Glyburide
,9551701,Peak serum,"Peak serum values of M1 (24-85 ng.ml(-1) vs 16-57 ng.ml(-1)), M2 (7-22 ng.ml(-1) vs <5-18 ng.ml(-1)) and M1 + M2 (32-100 ng.ml(-1) vs 23-76 ng.",Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551701/),ng,23-76,205140,DB01016,Glyburide
,11678967,area under the curve values: AUC,"As expected there was a significant decrease in postprandial glycaemia after glibenclamide administration compared to placebo (mean area under the curve values: AUC = 53.3 +/- 18.2 and 69.1 +/- 21.6 mm/h, P = 0.00009).",Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678967/),[mm] / [h],53.3,207393,DB01016,Glyburide
,11678967,area under the curve values: AUC,"As expected there was a significant decrease in postprandial glycaemia after glibenclamide administration compared to placebo (mean area under the curve values: AUC = 53.3 +/- 18.2 and 69.1 +/- 21.6 mm/h, P = 0.00009).",Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678967/),[mm] / [h],69.1,207394,DB01016,Glyburide
,3085419,peak concentration,"In 12 patients glibenclamide was rapidly absorbed, reaching a peak concentration of 138.0 +/- 15.8 ng/ml (mean +/- SEM) at about 2 h.",Interindividual variation in the absorption of glibenclamide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085419/),[ng] / [ml],138.0,223366,DB01016,Glyburide
,3085419,serum peak,"However, in 5 patients the absorption of glibenclamide was delayed and reached a serum peak of 134.1 +/- 29.5 ng/ml at later than 4 h.",Interindividual variation in the absorption of glibenclamide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085419/),[ng] / [ml],134.1,223367,DB01016,Glyburide
,11951812,Tmax (time to maximal plasma concentration),"The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02).","Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11951812/),h,1.25,226840,DB01016,Glyburide
,11951812,Tn,"The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02).","Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11951812/),h,0.5,226841,DB01016,Glyburide
,23806476,Cmax,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [ml],39.7,231032,DB01016,Glyburide
,23806476,AUC,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],108,231033,DB01016,Glyburide
,23806476,AUC,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [ml],43.6,231034,DB01016,Glyburide
,23806476,AUC,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],133,231035,DB01016,Glyburide
,23806476,Cmax,"For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],91.1,231036,DB01016,Glyburide
,23806476,AUC,"For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],224,231037,DB01016,Glyburide
,23806476,AUC,"For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],324,231038,DB01016,Glyburide
,17973362,t1/2,Preliminary pharmacokinetic studies in dog demonstrated excellent oral bioavailability and a t1/2 of 15 h.,Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973362/),h,15,234361,DB01016,Glyburide
,14748619,bioavailability,"The pharmacokinetics of nateglinide are characterised by rapid absorption and elimination, with good (73%) bioavailability.","Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748619/),%,73,236941,DB01016,Glyburide
,27288758,flow rate,"The chromatographic separation was carried out in 15min on a Waters C18 column (150×3.9mm i.d., 4μm) with a mobile phase containing 0.2% formic acid and acetonitrile (1:1, v/v) at a flow rate of 0.4ml/min.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),[ml] / [min],0.4,247793,DB01016,Glyburide
,27288758,m,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,286.1,247794,DB01016,Glyburide
,27288758,m/,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,830.3,247795,DB01016,Glyburide
,27288758,m/z,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,494.2,247796,DB01016,Glyburide
,27288758,m/z,"The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),,369.0,247797,DB01016,Glyburide
above,27288758,recoveries,"The recoveries of PIP, DOX and IS were above 75% and there was no matrix effect.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),%,75,247798,DB01016,Glyburide
,27288758,bioavailability,"At the dose of 3.5mg/kg, the bioavailability of PIP was calculated to be 25.36%.",Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27288758/),%,25.36,247799,DB01016,Glyburide
,7821171,elimination half-life (t1/2,"A significant prolongation in the elimination half-life (t1/2: week 0, 4.0 +/- 1.9 h; week 6, 13.7 +/- 10.5 h; and week 12, 12.1 +/- 8.2 h) and an increased volume of distribution of glyburide was observed during chronic dosing.",Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7821171/),h,4.0,248169,DB01016,Glyburide
,7821171,elimination half-life (t1/2,"A significant prolongation in the elimination half-life (t1/2: week 0, 4.0 +/- 1.9 h; week 6, 13.7 +/- 10.5 h; and week 12, 12.1 +/- 8.2 h) and an increased volume of distribution of glyburide was observed during chronic dosing.",Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7821171/),h,13.7,248170,DB01016,Glyburide
,7821171,elimination half-life (t1/2,"A significant prolongation in the elimination half-life (t1/2: week 0, 4.0 +/- 1.9 h; week 6, 13.7 +/- 10.5 h; and week 12, 12.1 +/- 8.2 h) and an increased volume of distribution of glyburide was observed during chronic dosing.",Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7821171/),h,12.1,248171,DB01016,Glyburide
,8576296,volume of distribution,"Estimated mean volume of distribution, total and renal clearance of M1 and M2 were 20.8 +/- 8.4 litres, 11.9 +/- 1.7 litres/h, 13.5 +/- 3.7 litres/h and 15.5 +/- 5.5 litres, 10.4 +/- 1.3 litres/h, 8.6 +/- 1.6 litres/h, respectively.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),l,20.8,248517,DB01016,Glyburide
,8576296,total,"Estimated mean volume of distribution, total and renal clearance of M1 and M2 were 20.8 +/- 8.4 litres, 11.9 +/- 1.7 litres/h, 13.5 +/- 3.7 litres/h and 15.5 +/- 5.5 litres, 10.4 +/- 1.3 litres/h, 8.6 +/- 1.6 litres/h, respectively.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),[l] / [h],11.9,248518,DB01016,Glyburide
,8576296,total,"Estimated mean volume of distribution, total and renal clearance of M1 and M2 were 20.8 +/- 8.4 litres, 11.9 +/- 1.7 litres/h, 13.5 +/- 3.7 litres/h and 15.5 +/- 5.5 litres, 10.4 +/- 1.3 litres/h, 8.6 +/- 1.6 litres/h, respectively.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),l,15.5,248519,DB01016,Glyburide
,8576296,total,"Estimated mean volume of distribution, total and renal clearance of M1 and M2 were 20.8 +/- 8.4 litres, 11.9 +/- 1.7 litres/h, 13.5 +/- 3.7 litres/h and 15.5 +/- 5.5 litres, 10.4 +/- 1.3 litres/h, 8.6 +/- 1.6 litres/h, respectively.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),[l] / [h],10.4,248520,DB01016,Glyburide
,8576296,renal clearance,"Estimated mean volume of distribution, total and renal clearance of M1 and M2 were 20.8 +/- 8.4 litres, 11.9 +/- 1.7 litres/h, 13.5 +/- 3.7 litres/h and 15.5 +/- 5.5 litres, 10.4 +/- 1.3 litres/h, 8.6 +/- 1.6 litres/h, respectively.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),[l] / [h],8.6,248521,DB01016,Glyburide
,8576296,volume of distribution,"Estimates of the volume of distribution and total clearance were significantly higher than those of Gb, which were 7.44 +/- 1.53 litres, 4.42 +/- 0.56 litres/h intravenously and 9.32 +/- 2.79 litres, 4.09 +/- 0.45 litres/h orally.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),l,7.44,248522,DB01016,Glyburide
,8576296,volume of distribution,"Estimates of the volume of distribution and total clearance were significantly higher than those of Gb, which were 7.44 +/- 1.53 litres, 4.42 +/- 0.56 litres/h intravenously and 9.32 +/- 2.79 litres, 4.09 +/- 0.45 litres/h orally.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),l,9.32,248523,DB01016,Glyburide
,8576296,total clearance,"Estimates of the volume of distribution and total clearance were significantly higher than those of Gb, which were 7.44 +/- 1.53 litres, 4.42 +/- 0.56 litres/h intravenously and 9.32 +/- 2.79 litres, 4.09 +/- 0.45 litres/h orally.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),[l] / [h],4.42,248524,DB01016,Glyburide
,8576296,total clearance,"Estimates of the volume of distribution and total clearance were significantly higher than those of Gb, which were 7.44 +/- 1.53 litres, 4.42 +/- 0.56 litres/h intravenously and 9.32 +/- 2.79 litres, 4.09 +/- 0.45 litres/h orally.",Comparison of the kinetics of glyburide and its active metabolites in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8576296/),[l] / [h],4.09,248525,DB01016,Glyburide
,7988624,maximal glibenclamide plasma concentrations,The maximal glibenclamide plasma concentrations were significantly higher in the normoglycaemic than in the hyperglycaemic state (448 vs 228 mg.l-1) and these peak concentrations were attained faster in normoglycaemia than in hyperglycaemia (3.7 vs 5 h).,The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988624/),[mg] / [l],448,250433,DB01016,Glyburide
,7988624,maximal glibenclamide plasma concentrations,The maximal glibenclamide plasma concentrations were significantly higher in the normoglycaemic than in the hyperglycaemic state (448 vs 228 mg.l-1) and these peak concentrations were attained faster in normoglycaemia than in hyperglycaemia (3.7 vs 5 h).,The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988624/),[mg] / [l],228,250434,DB01016,Glyburide
,31980499,arterial-to-venous plasma concentration ratio,"Mean metformin umbilical cord arterial-to-venous plasma concentration ratio was 1.0 ± 0.1, venous umbilical cord-to-maternal concentration ratio was 1.4 ± 0.5, and arterial umbilical cord-to-maternal concentration ratio was 1.5 ± 0.5.",Effects of Pregnancy on the Pharmacokinetics of Metformin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31980499/),,1.0,261577,DB01016,Glyburide
,31980499,venous umbilical cord-to-maternal concentration ratio,"Mean metformin umbilical cord arterial-to-venous plasma concentration ratio was 1.0 ± 0.1, venous umbilical cord-to-maternal concentration ratio was 1.4 ± 0.5, and arterial umbilical cord-to-maternal concentration ratio was 1.5 ± 0.5.",Effects of Pregnancy on the Pharmacokinetics of Metformin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31980499/),,1.4,261578,DB01016,Glyburide
,31980499,arterial umbilical cord-to-maternal concentration ratio,"Mean metformin umbilical cord arterial-to-venous plasma concentration ratio was 1.0 ± 0.1, venous umbilical cord-to-maternal concentration ratio was 1.4 ± 0.5, and arterial umbilical cord-to-maternal concentration ratio was 1.5 ± 0.5.",Effects of Pregnancy on the Pharmacokinetics of Metformin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31980499/),,1.5,261579,DB01016,Glyburide
,17011248,flow rate,"The chromatographic separation was achieved on a monolithic octadecyl chemically modified silicagel column and a mobile phase containing 42% aqueous 0.1% HCOOH solution (v/v) and 58% acetonitrile, at a flow rate of 1 mL/min, in isocratic conditions.",Determination of glibenclamide in human plasma by liquid chromatography and atmospheric pressure chemical ionization/MS-MS detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17011248/),[ml] / [min],1,262507,DB01016,Glyburide
,17011248,recovery,The mean recovery for glibenclamide was 98.1+/-2.8% over a concentration interval ranging from 1 to 500 ng/mL.,Determination of glibenclamide in human plasma by liquid chromatography and atmospheric pressure chemical ionization/MS-MS detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17011248/),%,98.1,262508,DB01016,Glyburide
,8237389,sensitivity,A selective HPLC method with a uv spectrophotometric detector (sensitivity: 16 ng.ml-1) was established for determining serum Gli concentration.,Pharmacokinetics and relative bioavailability of tablet of micronized glibenclamide in 4 Chinese healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237389/),[ng] / [ml],16,269604,DB01016,Glyburide
,8237389,Cmax,Cmax for RG was 212 +/- 41 ng.,Pharmacokinetics and relative bioavailability of tablet of micronized glibenclamide in 4 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237389/),ng,212,269605,DB01016,Glyburide
,8237389,Tmax,"Tmax for RG and MG were 3.5 +/- 0.6 and 2.2 +/- 0.3 h, respectively.",Pharmacokinetics and relative bioavailability of tablet of micronized glibenclamide in 4 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237389/),h,3.5,269606,DB01016,Glyburide
,8237389,Tmax,"Tmax for RG and MG were 3.5 +/- 0.6 and 2.2 +/- 0.3 h, respectively.",Pharmacokinetics and relative bioavailability of tablet of micronized glibenclamide in 4 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237389/),h,2.2,269607,DB01016,Glyburide
,8237389,relative oral bioavailability,"The relative oral bioavailability of MG was found to be 77%, increased approximately 1.7-fold that of RG.",Pharmacokinetics and relative bioavailability of tablet of micronized glibenclamide in 4 Chinese healthy men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237389/),%,77,269608,DB01016,Glyburide
,17060062,"AUCss,tau","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],2594.8,273249,DB01016,Glyburide
,17060062,"AUCss,tau","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],2443.7,273250,DB01016,Glyburide
,17060062,"Css,max","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[ng] / [ml],479.3,273251,DB01016,Glyburide
,17060062,"Css,max","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[ng] / [ml],462.7,273252,DB01016,Glyburide
,17060062,"AUCss,tau","For glibenclamide, the mean AUCss,tau values were 525.7 ng x h/ml for monotherapy and 518.7 ng x h/ml for its combination with olmesartan.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],525.7,273253,DB01016,Glyburide
,17060062,"AUCss,tau","For glibenclamide, the mean AUCss,tau values were 525.7 ng x h/ml for monotherapy and 518.7 ng x h/ml for its combination with olmesartan.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],518.7,273254,DB01016,Glyburide
,17060062,"time to reach Css,max (tmax)","The median time to reach Css,max (tmax) for glibenclamide was shifted from 2.0 h to 1.0 h when combined with olmesartan, whereas the median tmax values for olmesartan remained unchanged at 1.5 h.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),h,2.0,273255,DB01016,Glyburide
,17060062,"time to reach Css,max (tmax)","The median time to reach Css,max (tmax) for glibenclamide was shifted from 2.0 h to 1.0 h when combined with olmesartan, whereas the median tmax values for olmesartan remained unchanged at 1.5 h.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),h,1.0,273256,DB01016,Glyburide
,17060062,tmax,"The median time to reach Css,max (tmax) for glibenclamide was shifted from 2.0 h to 1.0 h when combined with olmesartan, whereas the median tmax values for olmesartan remained unchanged at 1.5 h.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),h,1.5,273257,DB01016,Glyburide
